Basic Description

Product Name	AKT1 Mouse mAb - Primary antibody, for WB,Flow,ELISA,IF,ICC various applications, from Human, generated in Mouse, specific to AKT1, IgG1
Synonyms	EC 2.7.11.1 \| PKB \| PKB alpha \| Protein kinase B \| Protein kinase B alpha \| Proto-oncogene c-Akt \| RAC-PK-alpha
Specifications & Purity	ExactAb™, Validated, Carrier Free, 1.0mg/mL
Host Species	Mouse
Host species	Mouse
Specificity	AKT1
Application	WB,Flow,ELISA,IF,ICC
Immunogen	Purified recombinant fragment of human AKT1 (AA: 1-150) expressed in E. Coli.
Positive Control	WB: Recombinant human AKT1 (aa 1-150); MCF7, NIH/3T3, COS-7 and C6 cell lysates; AKT1 (aa 1-150)-hIgGFc transfected HEK-293 whole cell lysate. ICC/IF: HepG2 cells. Flow: HeLa cells.
Conjugation	Unconjugated
Grade	Carrier Free, ExactAb™, Validated
Product Description	Application: WB: 1/500 - 1/2000 IF/ICC: 1/200 - 1/1000 Flow: 1/200 - 1/400 ELISA: 1/10000 Protein Function Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly.

Product Properties

Antibody Type	Primary antibody
Clonality	Monoclonal antibodies
Isotype	IgG1
Light Chain Type	kappa
SDS-PAGE	150 kDa
Purification Method	Protein G purified
Source	Ascitic fluid
Form	Liquid
Concentration	1.0mg/mL
Storage Temp	Store at -20°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.

Images

AKT1 Mouse mAb (Ab087937) - Western Blot
All lanes: AKT1 Mouse mAb (Ab087937) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Mouse IgG H&L (HRP) (Ab138040) at 1/50000 dilution

Predicted band size: 55.7 kDa
Observed band size: 55.1 kDa

AKT1 Mouse mAb (Ab087937) - Flow Cytometry
Flow cytometric analysis of HeLa (human epithelial cell line from cervix adenocarcinoma) cell line labeling AKT1 with AKT1 Mouse mAb (Ab087937) at 1/200 dilution (green) compared with a negative control (red).

AKT1 Mouse mAb (Ab087937) - ICC/IF
HepG2 (human liver hepatocellular carcinoma cell line) cells stained for AKT1 (green) using AKT1 Mouse mAb (Ab087937) in ICC/IF. Blue: DRAQ5 DNA dye. Red: Actin filaments stained with AlexaFluor®-555-Phalloidin.

Associated Targets(Human)

AKT1 Tchem RAC-alpha serine/threonine-protein kinase (0 Activities)

Discover Target: AKT1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

AKT1 Tchem Serine/threonine-protein kinase AKT (9192 Activities)

Discover Target: AKT1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

AKT1 Tchem VHL/AKT1 (26 Activities)

Discover Target: AKT1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Application

Application	Dilution info
WB	1/500-1/2000 "> 1/500-1/2000
IF/ICC	1/200-1/1000 "> 1/200-1/1000
Flow Cytometry	1/200-1/400
ELISA	1/10000 "> 1/10000

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot Number	Certificate Type	Date	Item
ZJ23F0700655	Certificate of Analysis	Jul 21, 2023	Ab087937
ZJ23F0700656	Certificate of Analysis	Jul 21, 2023	Ab087937

FAQs and Articles

FAQ

Immunohistochemistry staining with samples in paraffin (IHC-P)

Categories: Protocols

Tags:

Monoclonal antibody Paraffin Section Immunohistochemistry/IHC

Citations of This Product

How to Cite Aladdin Scientific Products?

1. Zhu P,Qian J,Xu Z,Meng C,Liu J,Shan W,Zhu W,Wang Y,Yang Y,Zhang W,Zhang Y,Ling Y. (2020) Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling.. J Nat Prod, 83 (10.0): (3041-3049). [PMID:33026807] [10.1021/acs.jnatprod.0c00599]

References

1. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.. Science, 307 (5712): (1098-101). [PMID:15718470] [10.1021/op500134e]
2. Heerding DA, Rhodes N, Leber JD, Clark TJ, Keenan RM, Lafrance LV, Li M, Safonov IG, Takata DT, Venslavsky JW et al.. (2008) Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.. J Med Chem, 51 (18): (5663-79). [PMID:18800763] [10.1021/op500134e]
3. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al.. (2012) 7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.. J Med Chem, 55 (1): (403-13). [PMID:22136433] [10.1021/op500134e]
4. Addie M, Ballard P, Buttar D, Crafter C, Currie G, Davies BR, Debreczeni J, Dry H, Dudley P, Greenwood R et al.. (2013) Discovery of 4-Amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases.. J Med Chem, 56 (5): (2059-73). [PMID:23394218] [10.1021/op500134e]
5. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M et al.. (2010) Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt).. J Med Chem, 53 (5): (2239-49). [PMID:20151677] [10.1021/op500134e]
6. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LA, Das J, Doweyko AM et al.. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.. J Med Chem, 47 (27): (6658-61). [PMID:15615512] [10.1021/op500134e]
7. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ. (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one.. J Biol Chem, 282 (33): (24463-70). [PMID:17562705] [10.1021/op500134e]
8. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099] [10.1021/op500134e]
9. Oyarzabal J, Zarich N, Albarran MI, Palacios I, Urbano-Cuadrado M, Mateos G, Reymundo I, Rabal O, Salgado A, Corrionero A et al.. (2010) Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.. J Med Chem, 53 (18): (6618-28). [PMID:20722422] [10.1021/op500134e]
10. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al.. (2009) p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.. J Med Chem, 52 (20): (6257-69). [PMID:19772287] [10.1021/op500134e]
11. Dumble M, Crouthamel MC, Zhang SY, Schaber M, Levy D, Robell K, Liu Q, Figueroa DJ, Minthorn EA, Seefeld MA et al.. (2014) Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.. PLoS ONE, 9 (6): (e100880). [PMID:24978597] [10.1021/op500134e]
12. Cheng H, Li C, Bailey S, Baxi SM, Goulet L, Guo L, Hoffman J, Jiang Y, Johnson TO, Johnson TW et al.. (2013) Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.. ACS Med Chem Lett, 4 (1): (91-7). [PMID:24900568] [10.1021/op500134e]
13. Venkatesan AM, Dehnhardt CM, Delos Santos E, Chen Z, Dos Santos O, Ayral-Kaloustian S, Khafizova G, Brooijmans N, Mallon R, Hollander I et al.. (2010) Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.. J Med Chem, 53 (6): (2636-45). [PMID:20166697] [10.1021/op500134e]
14. Engler TA, Henry JR, Malhotra S, Cunningham B, Furness K, Brozinick J, Burkholder TP, Clay MP, Clayton J, Diefenbacher C et al.. (2004) Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.. J Med Chem, 47 (16): (3934-7). [PMID:15267232] [10.1021/op500134e]
15. Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP et al.. (2011) Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.. J Med Chem, 54 (6): (1871-95). [PMID:21341675] [10.1021/op500134e]
16. Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S. (2009) Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.. Bioorg Med Chem, 17 (19): (6983-92). [PMID:19734051] [10.1021/op500134e]
17. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL et al.. (2007) Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.. J Pharmacol Exp Ther, 320 (1): (89-98). [PMID:17018693] [10.1021/op500134e]
18. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, Rizzuti BJ, Sawyer PS, Perry BD, Brissette WH et al.. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.. Science, 302 (5646): (875-8). [PMID:14593182] [10.1021/op500134e]
19. Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS. (2011) Identification and characterization of a novel integrin-linked kinase inhibitor.. J Med Chem, 54 (18): (6364-74). [PMID:21823616] [10.1021/op500134e]
20. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. (1998) Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase.. Proc Natl Acad Sci USA, 95 (19): (11211-6). [PMID:9736715] [10.1021/op500134e]
21. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C. (2009) Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).. J Med Chem, 52 (20): (6433-46). [PMID:19788238] [10.1021/op500134e]
22. Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM et al.. (2012) Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2).. Medchemcomm, 3 (6): (699-709). [PMID:23275831] [10.1021/op500134e]
23. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al.. (2012) Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.. J Med Chem, 55 (2): (903-13). [PMID:22148921] [10.1021/op500134e]
24. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al.. (2015) Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.. J Med Chem, 58 (17): (6875-98). [PMID:26222319] [10.1021/op500134e]
25. Bravo-Altamirano K, George KM, Frantz MC, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P. (2011) Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D.. ACS Med Chem Lett, 2 (2): (154-159). [PMID:21617763] [10.1021/op500134e]
26. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al.. (2011) Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 21 (21): (6258-63). [PMID:21958547] [10.1021/op500134e]
27. Lapierre JM, Eathiraj S, Vensel D, Liu Y, Bull CO, Cornell-Kennon S, Iimura S, Kelleher EW, Kizer DE, Koerner S et al.. (2016) Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.. J Med Chem, 59 (13): (6455-69). [PMID:27305487] [10.1021/op500134e]
28. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640] [10.1021/op500134e]
29. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al.. (2015) Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.. J Med Chem, 58 (21): (8373-86). [PMID:26505898] [10.1021/op500134e]
30. Mandal PK, Morlacchi P, Knight JM, Link TM, Lee 4th GR, Nurieva R, Singh D, Dhanik A, Kavraki L, Corry DB et al.. (2015) Targeting the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 6 (STAT6) with Cell-Permeable, Phosphatase-Stable Phosphopeptide Mimics Potently Inhibits Tyr641 Phosphorylation and Transcriptional Activity.. J Med Chem, 58 (22): (8970-84). [PMID:26506089] [10.1021/op500134e]
31. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al.. (2015) Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).. J Med Chem, 58 (20): (8182-99). [PMID:26431428] [10.1021/op500134e]
32. Das J, Furch JA, Liu C, Moquin RV, Lin J, Spergel SH, McIntyre KW, Shuster DJ, O'Day KD, Penhallow B et al.. (2006) Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.. Bioorg Med Chem Lett, 16 (14): (3706-12). [PMID:16682193] [10.1021/op500134e]
33. Wu Y, Wang B, Wang J, Qi S, Zou F, Qi Z, Liu F, Liu Q, Chen C, Hu C et al.. (2019) Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors.. J Med Chem, 62 (13): (6083-6101). [PMID:31250638] [10.1021/op500134e]
34. De SK, Stebbins JL, Chen LH, Riel-Mehan M, Machleidt T, Dahl R, Yuan H, Emdadi A, Barile E, Chen V et al.. (2009) Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-Jun N-terminal kinase.. J Med Chem, 52 (7): (1943-52). [PMID:19271755] [10.1021/op500134e]
35. Alam MM, Joh EH, Park H, Kim B, Kim DH, Lee YS. (2013) Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines.. Bioorg Med Chem, 21 (7): (2018-24). [PMID:23415083] [10.1021/op500134e]
36. Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J et al.. (2014) Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.. Cancer Res, 74 (16): (4458-69). [PMID:24934808] [10.1021/op500134e]
37. Erki Enkvist, Darja Lavogina, Gerda Raidaru, Angela Vaasa, Indrek Viil, Marje Lust, Kaido Viht, Asko Uri,. (2006-11-28) Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases.. Journal of medicinal chemistry, 49 ((24)): ( 7150-7159 ). [PMID:17125267]
38. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong. (2013-04-23) Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant.. Journal of medicinal chemistry, 56 ((9)): (3531-3545). [PMID:23600806]
39. Tze-chen Hsieh,Chia-Yi Lin,Dylan John Bennett,Erxi Wu,Joseph M Wu. (2014-06-27) Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2.. PloS one, 9 ((6)): (e101070-e101070). [PMID:24968355]
40. Ajit Dhananjay Jagtap,Pei-Teh Chang,Jia-Rong Liu,Hsiao-Chun Wang,Nagendra B Kondekar,Li-Jiuan Shen,Hsiang-Wen Tseng,Grace Shiahuy Chen,Ji-Wang Chern. (2014-08-05) Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.. European journal of medicinal chemistry, 85 (268-288). [PMID:25089810]
41. Tingting Li,Xian Wang,Enguo Ju,Suzane Ramos da Silva,Luping Chen,Xinquan Zhang,Shan Wei,Shou-Jiang Gao. (2021-02-18) RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation.. Nature communications, 12 ((1)): (1055-1055). [PMID:33594058]
42. Yi-Nan Zhang,Wei Zhang,Di Hong,Lei Shi,Qiang Shen,Jing-Ya Li,Jia Li,Li-Hong Hu. (2008-08-19) Oleanolic acid and its derivatives: new inhibitor of protein tyrosine phosphatase 1B with cellular activities.. Bioorganic & medicinal chemistry, 16 ((18)): (8697-8705). [PMID:18707891]
43. SeCheol Oh,Navid Paknejad,Richard K Hite. (2020-04-02) Gating and selectivity mechanisms for the lysosomal K+ channel TMEM175.. eLife, 9 [PMID:32228865]
44. Daqian Xu,Zheng Wang,Yan Xia,Fei Shao,Weiya Xia,Yongkun Wei,Xinjian Li,Xu Qian,Jong-Ho Lee,Linyong Du,Yanhua Zheng,Guishuai Lv,Jia-Shiun Leu,Hongyang Wang,Dongming Xing,Tingbo Liang,Mien-Chie Hung,Zhimin Lu. (2020-04-24) The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.. Nature, 580 ((7804)): (530-535). [PMID:32322062]
45. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.. (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 45 (6): (1300-1312). [PMID:11881999] [10.1021/jm011022e]
46. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA.. (2004) 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.. J Med Chem, 47 (13): (3367-3380). [PMID:15189033] [10.1021/jm031145u]
47. VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, Toogood PL.. (2005) Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.. J Med Chem, 48 (7): (2371-2387). [PMID:15801830] [10.1021/jm049355+]
48. McDermott LA, Higgins B, Simcox M, Luk KC, Nevins T, Kolinsky K, Smith M, Yang H, Li JK, Chen Y, Ke J, Mallalieu N, Egan T, Kolis S, Railkar A, Gerber L, Liu JJ, Konzelmann F, Zhang Z, Flynn T, Morales O, Chen Y.. (2006) Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.. Bioorg Med Chem Lett, 16 (7): (1950-1953). [PMID:16460940] [10.1016/j.bmcl.2005.12.092]
49. Barve V, Ahmed F, Adsule S, Banerjee S, Kulkarni S, Katiyar P, Anson CE, Powell AK, Padhye S, Sarkar FH.. (2006) Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells.. J Med Chem, 49 (13): (3800-3808). [PMID:16789737] [10.1021/jm051068y]
50. Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ.. (2006) Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.. J Med Chem, 49 (13): (3766-3769). [PMID:16789733] [10.1021/jm060347y]
51. Zhu GD, Gandhi VB, Gong J, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Jarvis K, Park C, Jong RD, Oltersdorf T, Li Q, Rosenberg SH, Giranda VL.. (2006) Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers.. Bioorg Med Chem Lett, 16 (13): (3424-3429). [PMID:16644221] [10.1016/j.bmcl.2006.04.005]
52. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cee VJ, Chai L, Deak HL, Epstein LF, Faust T, Gallant P, Geuns-Meyer SD, Gore A, Gu Y, Henkle B, Hodous BL, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, Masse CE, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, White RD, Zhao H, Zhu L, Zhu X.. (2006) Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.. J Med Chem, 49 (19): (5671-5686). [PMID:16970394] [10.1021/jm0605482]
53. Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M.. (2006) 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.. J Med Chem, 49 (22): (6500-6509). [PMID:17064068] [10.1021/jm0605740]
54. Chao WR, Yean D, Amin K, Green C, Jong L.. (2007) Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling.. J Med Chem, 50 (15): (3412-3415). [PMID:17602463] [10.1021/jm070040e]
55. Bruno O, Brullo C, Bondavalli F, Schenone S, Ranise A, Arduino N, Bertolotto MB, Montecucco F, Ottonello L, Dallegri F, Tognolini M, Ballabeni V, Bertoni S, Barocelli E.. (2007) Synthesis and biological evaluation of N-pyrazolyl-N'-alkyl/benzyl/phenylureas: a new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis.. J Med Chem, 50 (15): (3618-3626). [PMID:17608466] [10.1021/jm0704402]
56. Conchon E, Anizon F, Aboab B, Prudhomme M.. (2007) Synthesis and biological activities of new checkpoint kinase 1 inhibitors structurally related to granulatimide.. J Med Chem, 50 (19): (4669-4680). [PMID:17722905] [10.1021/jm070664k]
57. Singh RK, Lange TS, Kim K, Zou Y, Lieb C, Sholler GL, Brard L.. (2007) Effect of indole ethyl isothiocyanates on proliferation, apoptosis, and MAPK signaling in neuroblastoma cell lines.. Bioorg Med Chem Lett, 17 (21): (5846-5852). [PMID:17855093] [10.1016/j.bmcl.2007.08.032]
58. Manetti F, Santucci A, Locatelli GA, Maga G, Spreafico A, Serchi T, Orlandini M, Bernardini G, Caradonna NP, Spallarossa A, Brullo C, Schenone S, Bruno O, Ranise A, Bondavalli F, Hoffmann O, Bologna M, Angelucci A, Botta M.. (2007) Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice.. J Med Chem, 50 (23): (5579-5588). [PMID:17929792] [10.1021/jm061449r]
59. Itoh T, Ito Y, Ohguchi K, Ohyama M, Iinuma M, Otsuki Y, Nozawa Y, Akao Y.. (2008) Eupalinin A isolated from Eupatorium chinense L. induces autophagocytosis in human leukemia HL60 cells.. Bioorg Med Chem, 16 (2): (721-731). [PMID:17980607] [10.1016/j.bmc.2007.10.033]
60. Jang SW, Okada M, Sayeed I, Xiao G, Stein D, Jin P, Ye K.. (2007) Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death.. Proc Natl Acad Sci U S A, 104 (41): (16329-16334). [PMID:17911251] [10.1073/pnas.0706662104]
61. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT.. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor.. J Biol Chem, 282 (20): (14845-14852). [PMID:17395594] [10.1074/jbc.m606695200]
62. Su JL, Yang CY, Zhao M, Kuo ML, Yen ML.. (2007) Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol.. J Biol Chem, 282 (27): (19385-19398). [PMID:17513867] [10.1074/jbc.m702452200]
63. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.. (2008) Design, synthesis, and biological evaluation of potent c-Met inhibitors.. J Med Chem, 51 (18): (5766-5779). [PMID:18763753] [10.1021/jm8006189]
64. Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, Greco R, Huang X, Joseph-McCarthy D, Kelly MF, Kirisits M, Lee J, Li Y, Morgan P, Stock JR, Tsao DH, Wissner A, Yang X, Chaudhary D.. (2008) Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.. J Med Chem, 51 (19): (5958-5963). [PMID:18783200] [10.1021/jm800214a]
65. Kayser-Bricker KJ, Glenn MP, Lee SH, Sebti SM, Cheng JQ, Hamilton AD.. (2009) Non-peptidic substrate-mimetic inhibitors of Akt as potential anti-cancer agents.. Bioorg Med Chem, 17 (4): (1764-1771). [PMID:19179081] [10.1016/j.bmc.2008.09.058]
66. De SK, Chen LH, Stebbins JL, Machleidt T, Riel-Mehan M, Dahl R, Chen V, Yuan H, Barile E, Emdadi A, Murphy R, Pellecchia M.. (2009) Discovery of 2-(5-nitrothiazol-2-ylthio)benzo[d]thiazoles as novel c-Jun N-terminal kinase inhibitors.. Bioorg Med Chem, 17 (7): (2712-2717). [PMID:19282190] [10.1016/j.bmc.2009.02.046]
67. Lin JC, Yang SC, Hong TM, Yu SL, Shi Q, Wei L, Chen HY, Yang PC, Lee KH.. (2009) Phenanthrene-based tylophorine-1 (PBT-1) inhibits lung cancer cell growth through the Akt and NF-kappaB pathways.. J Med Chem, 52 (7): (1903-1911). [PMID:19284764] [10.1021/jm801344j]
68. Gopalsamy A, Ciszewski G, Hu Y, Lee F, Feldberg L, Frommer E, Kim S, Collins K, Wojciechowicz D, Mallon R.. (2009) Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.. Bioorg Med Chem Lett, 19 (10): (2735-2738). [PMID:19362830] [10.1016/j.bmcl.2009.03.129]
69. Yang X, Shi Q, Liu YN, Zhao G, Bastow KF, Lin JC, Yang SC, Yang PC, Lee KH.. (2009) Antitumor agents 268. Design, synthesis, and mechanistic studies of new 9-substituted phenanthrene-based tylophorine analogues as potent cytotoxic agents.. J Med Chem, 52 (16): (5262-5268). [PMID:19645447] [10.1021/jm9009263]
70. Lumeras W, Caturla F, Vidal L, Esteve C, Balagué C, Orellana A, Domínguez M, Roca R, Huerta JM, Godessart N, Vidal B.. (2009) Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.. J Med Chem, 52 (17): (5531-5545). [PMID:19678708] [10.1021/jm9008604]
71. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH.. (2009) Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.. Bioorg Med Chem Lett, 19 (16): (4720-4723). [PMID:19596575] [10.1016/j.bmcl.2009.06.066]
72. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS.. (2009) Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.. J Med Chem, 52 (21): (6880-6888). [PMID:19888761] [10.1021/jm901146p]
73. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM.. (2009) Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles.. Bioorg Med Chem Lett, 19 (22): (6293-6297). [PMID:19822424] [10.1016/j.bmcl.2009.09.094]
74. Dong Y, Shi Q, Pai HC, Peng CY, Pan SL, Teng CM, Nakagawa-Goto K, Yu D, Liu YN, Wu PC, Bastow KF, Morris-Natschke SL, Brossi A, Lang JY, Hsu JL, Hung MC, Lee EY, Lee KH.. (2010) Antitumor agents. 272. Structure-activity relationships and in vivo selective anti-breast cancer activity of novel neo-tanshinlactone analogues.. J Med Chem, 53 (5): (2299-2308). [PMID:20148565] [10.1021/jm1000858]
75. De SK, Chen V, Stebbins JL, Chen LH, Cellitti JF, Machleidt T, Barile E, Riel-Mehan M, Dahl R, Yang L, Emdadi A, Murphy R, Pellecchia M.. (2010) Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors.. Bioorg Med Chem, 18 (2): (590-596). [PMID:20045647] [10.1016/j.bmc.2009.12.013]
76. Velankar AD, Quintini G, Prabhu A, Weber A, Hunaeus G, Voland B, Wuest M, Orjeda C, Harel D, Varghese S, Gore V, Patil M, Gayke D, Herdemann M, Heit I, Zaliani A.. (2010) Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).. Bioorg Med Chem, 18 (12): (4547-4559). [PMID:20472447] [10.1016/j.bmc.2010.04.056]
77. Li Q, Wu J, Zheng H, Liu K, Guo TL, Liu Y, Eblen ST, Grant S, Zhang S.. (2010) Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.. Bioorg Med Chem Lett, 20 (15): (4526-4530). [PMID:20580230] [10.1016/j.bmcl.2010.06.030]
78. Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T.. (2010) A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.. J Med Chem, 53 (15): (5439-5448). [PMID:20604564] [10.1021/jm901808w]
79. Samadi AK, Tong X, Mukerji R, Zhang H, Timmermann BN, Cohen MS.. (2010) Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma.. J Nat Prod, 73 (9): (1476-1481). [PMID:20726569] [10.1021/np100112p]
80. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, Litz J, Clement CC, Kang Y, She Y, Wu N, Felts S, Wipf P, Massague J, Jiang X, Brodsky JL, Krystal GW, Chiosis G.. (2007) Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.. Nat Chem Biol, 3 (8): (498-507). [PMID:17603540] [10.1038/nchembio.2007.10]
81. Terazawa R, Garud DR, Hamada N, Fujita Y, Itoh T, Nozawa Y, Nakane K, Deguchi T, Koketsu M, Ito M.. (2010) Identification of organoselenium compounds that possess chemopreventive properties in human prostate cancer LNCaP cells.. Bioorg Med Chem, 18 (19): (7001-7008). [PMID:20805033] [10.1016/j.bmc.2010.08.019]
82. Kim EJ, Love DC, Darout E, Abdo M, Rempel B, Withers SG, Rablen PR, Hanover JA, Knapp S.. (2010) OGA inhibition by GlcNAc-selenazoline.. Bioorg Med Chem, 18 (19): (7058-7064). [PMID:20822912] [10.1016/j.bmc.2010.08.010]
83. Blake JF, Kallan NC, Xiao D, Xu R, Bencsik JR, Skelton NJ, Spencer KL, Mitchell IS, Woessner RD, Gloor SL, Risom T, Gross SD, Martinson M, Morales TH, Vigers GP, Brandhuber BJ.. (2010) Discovery of pyrrolopyrimidine inhibitors of Akt.. Bioorg Med Chem Lett, 20 (19): (5607-5612). [PMID:20810279] [10.1016/j.bmcl.2010.08.053]
84. Karelia N, Desai D, Hengst JA, Amin S, Rudrabhatla SV, Yun J.. (2010) Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.. Bioorg Med Chem Lett, 20 (22): (6816-6819). [PMID:20855208] [10.1016/j.bmcl.2010.08.113]
85. Ye P, Kuhn C, Juan M, Sharma R, Connolly B, Alton G, Liu H, Stanton R, Kablaoui NM.. (2011) Potent and selective thiophene urea-templated inhibitors of S6K.. Bioorg Med Chem Lett, 21 (2): (849-852). [PMID:21185721] [10.1016/j.bmcl.2010.11.069]
86. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM.. (2011) Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.. Bioorg Med Chem, 19 (6): (1915-1923). [PMID:21353571] [10.1016/j.bmc.2011.01.067]
87. Ren X, Duan L, He Q, Zhang Z, Zhou Y, Wu D, Pan J, Pei D, Ding K, Ding K.. (2010) Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway.. ACS Med Chem Lett, 1 (9): (454-459). [PMID:24900231] [10.1021/ml100146z]
88. De SK, Barile E, Chen V, Stebbins JL, Cellitti JF, Machleidt T, Carlson CB, Yang L, Dahl R, Pellecchia M.. (2011) Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase.. Bioorg Med Chem, 19 (8): (2582-2588). [PMID:21458276] [10.1016/j.bmc.2011.03.017]
89. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC, Liao WS, McMurray JS.. (2011) Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.. J Med Chem, 54 (10): (3549-3563). [PMID:21486047] [10.1021/jm2000882]
90. Fiorino F, Magli E, Perissutti E, Severino B, Frecentese F, Esposito A, De Angelis F, Incisivo GM, Massarelli P, Nencini C, Di Gennaro E, Budillon A, Di Cintio A, Santagada V, Caliendo G.. (2011) Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents.. Eur J Med Chem, 46 (6): (2206-2216). [PMID:21440338] [10.1016/j.ejmech.2011.03.001]
91. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P.. (2011) Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.. Bioorg Med Chem, 19 (15): (4644-4651). [PMID:21741249] [10.1016/j.bmc.2011.06.013]
92. Chavez SA, Martinko AJ, Lau C, Pham MN, Cheng K, Bevan DE, Mollnes TE, Yin H.. (2011) Development of β-amino alcohol derivatives that inhibit Toll-like receptor 4 mediated inflammatory response as potential antiseptics.. J Med Chem, 54 (13): (4659-4669). [PMID:21591694] [10.1021/jm2003365]
93. Krishnegowda G, Prakasha Gowda AS, Tagaram HR, Carroll KF, Irby RB, Sharma AK, Amin S.. (2011) Synthesis and biological evaluation of a novel class of isatin analogs as dual inhibitors of tubulin polymerization and Akt pathway.. Bioorg Med Chem, 19 (20): (6006-6014). [PMID:21920762] [10.1016/j.bmc.2011.08.044]
94. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F.. (2011) 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.. J Med Chem, 54 (22): (7899-7910). [PMID:21999461] [10.1021/jm200975u]
95. Kim H, Kim M, Lee J, Yu H, Hah JM.. (2011) Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells.. Bioorg Med Chem, 19 (22): (6760-6767). [PMID:22014755] [10.1016/j.bmc.2011.09.042]
96. Powell NA, Kohrt JT, Filipski KJ, Kaufman M, Sheehan D, Edmunds JE, Delaney A, Wang Y, Bourbonais F, Lee DY, Schwende F, Sun F, McConnell P, Catana C, Chen H, Ohren J, Perrin LA.. (2012) Novel and selective spiroindoline-based inhibitors of Sky kinase.. Bioorg Med Chem Lett, 22 (1): (190-193). [PMID:22119469] [10.1016/j.bmcl.2011.11.036]
97. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA.. (2012) Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.. Eur J Med Chem, 48 (143-152). [PMID:22204902] [10.1016/j.ejmech.2011.12.006]
98. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS.. (2012) Characterization of TAE684 as a potent LRRK2 kinase inhibitor.. Bioorg Med Chem Lett, 22 (5): (1864-1869). [PMID:22335897] [10.1016/j.bmcl.2012.01.084]
99. Maryanoff BE, O'Neill JC, McComsey DF, Yabut SC, Luci DK, Jordan AD, Masucci JA, Jones WJ, Abad MC, Gibbs AC, Petrounia I.. (2011) Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.. ACS Med Chem Lett, 2 (7): (538-543). [PMID:24900346] [10.1021/ml200070g]
100. Kettle JG, Brown S, Crafter C, Davies BR, Dudley P, Fairley G, Faulder P, Fillery S, Greenwood H, Hawkins J, James M, Johnson K, Lane CD, Pass M, Pink JH, Plant H, Cosulich SC.. (2012) Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.. J Med Chem, 55 (3): (1261-1273). [PMID:22248236] [10.1021/jm201394e]
101. Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, Fry AM, Hoelder S.. (2012) Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity.. J Med Chem, 55 (7): (3228-3241). [PMID:22404346] [10.1021/jm201683b]
102. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B.. (2012) Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α.. J Med Chem, 55 (9): (4407-4424). [PMID:22533818] [10.1021/jm300309a]
103. Malmström J, Viklund J, Slivo C, Costa A, Maudet M, Sandelin C, Hiller G, Olsson LL, Aagaard A, Geschwindner S, Xue Y, Vasänge M.. (2012) Synthesis and structure-activity relationship of 4-(1,3-benzothiazol-2-yl)-thiophene-2-sulfonamides as cyclin-dependent kinase 5 (cdk5)/p25 inhibitors.. Bioorg Med Chem Lett, 22 (18): (5919-5923). [PMID:22889803] [10.1016/j.bmcl.2012.07.068]
104. Jester BW, Gaj A, Shomin CD, Cox KJ, Ghosh I.. (2012) Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen.. J Med Chem, 55 (4): (1526-1537). [PMID:22257127] [10.1021/jm201265f]
105. Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O.. (2012) Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.. J Med Chem, 55 (11): (5467-5482). [PMID:22548342] [10.1021/jm300403a]
106. Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ.. (2012) Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.. J Med Chem, 55 (17): (7392-7416). [PMID:22803810] [10.1021/jm300334d]
107. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B.. (2012) Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3.. Bioorg Med Chem Lett, 22 (24): (7634-7640). [PMID:23107479] [10.1016/j.bmcl.2012.10.016]
108. Pinson JA, Zheng Z, Miller MS, Chalmers DK, Jennings IG, Thompson PE.. (2013) L-Aminoacyl-triazine derivatives are isoform-selective PI3Kβ inhibitors that target non-conserved Asp862 of PI3Kβ. ACS Med Chem Lett, 4 (2): (206-210). [PMID:23795239] [10.1021/ml300336j]
109. Garofalo AW, Adler M, Aubele DL, Bowers S, Franzini M, Goldbach E, Lorentzen C, Neitz RJ, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong AP, Ye XM, Ren Z.. (2013) Novel cinnoline-based inhibitors of LRRK2 kinase activity.. Bioorg Med Chem Lett, 23 (1): (71-74). [PMID:23219325] [10.1016/j.bmcl.2012.11.021]
110. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP.. (2013) Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties.. J Med Chem, 56 (9): (3456-3466). [PMID:23550937] [10.1021/jm4002692]
111. Garofalo AW, Adler M, Aubele DL, Brigham EF, Chian D, Franzini M, Goldbach E, Kwong GT, Motter R, Probst GD, Quinn KP, Ruslim L, Sham HL, Tam D, Tanaka P, Truong AP, Ye XM, Ren Z.. (2013) Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors.. Bioorg Med Chem Lett, 23 (7): (1974-1977). [PMID:23453068] [10.1016/j.bmcl.2013.02.041]
112. Franzini M, Ye XM, Adler M, Aubele DL, Garofalo AW, Gauby S, Goldbach E, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong A, Ren Z.. (2013) Triazolopyridazine LRRK2 kinase inhibitors.. Bioorg Med Chem Lett, 23 (7): (1967-1973). [PMID:23454015] [10.1016/j.bmcl.2013.02.043]
113. Cheng H, Hoffman JE, Le PT, Pairish M, Kania R, Farrell W, Bagrodia S, Yuan J, Sun S, Zhang E, Xiang C, Dalvie D, Rahavendran SV.. (2013) Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.. Bioorg Med Chem Lett, 23 (9): (2787-2792). [PMID:23506825] [10.1016/j.bmcl.2013.02.020]
114. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709] [10.1016/j.bmc.2013.03.083]
115. Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y, Yu L.. (2013) A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity.. Eur J Med Chem, 65 (151-157). [PMID:23707920] [10.1016/j.ejmech.2013.04.058]
116. Akama T, Dong C, Virtucio C, Freund YR, Chen D, Orr MD, Jacobs RT, Zhang YK, Hernandez V, Liu Y, Wu A, Bu W, Liu L, Jarnagin K, Plattner JJ.. (2013) Discovery and structure-activity relationships of 6-(benzoylamino)benzoxaboroles as orally active anti-inflammatory agents.. Bioorg Med Chem Lett, 23 (21): (5870-5873). [PMID:24075731] [10.1016/j.bmcl.2013.08.096]
117. Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BD, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, Kaplan DR, Griffin C, Aman AM, Al-Awar R, Weiss S, Gunning PT.. (2013) Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma.. ACS Med Chem Lett, 4 (11): (1102-1107). [PMID:24900612] [10.1021/ml4003138]
118. Chen H, Guan Y, Yuan G, Zhang Q, Jing N.. (2014) A perylene derivative regulates HIF-1α and Stat3 signaling pathways.. Bioorg Med Chem, 22 (4): (1496-1505). [PMID:24485121] [10.1016/j.bmc.2013.10.018]
119. Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG.. (2014) Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.. Eur J Med Chem, 80 (154-166). [PMID:24780592] [10.1016/j.ejmech.2014.04.041]
120. Charoenrungruang S, Chanvorachote P, Sritularak B, Pongrakhananon V.. (2014) Gigantol, a bibenzyl from Dendrobium draconis, inhibits the migratory behavior of non-small cell lung cancer cells.. J Nat Prod, 77 (6): (1359-1366). [PMID:24844664] [10.1021/np500015v]
121. Lindsley CW.. (2014) 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.. J Med Chem, 57 (18): (7485-7498). [PMID:25180768] [10.1021/jm5011786]
122. Xie F, Zhu H, Zhang H, Lang Q, Tang L, Huang Q, Yu L.. (2015) In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor.. Eur J Med Chem, 89 (310-319). [PMID:25462247] [10.1016/j.ejmech.2014.10.044]
123. Avdieiev S, Gera L, Havrylyuk D, Hodges RS, Lesyk R, Ribrag V, Vassetzky Y, Kavsan V.. (2014) Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds.. Bioorg Med Chem, 22 (15): (3815-3823). [PMID:25012567] [10.1016/j.bmc.2014.06.046]
124. Muth F, Günther M, Bauer SM, Döring E, Fischer S, Maier J, Drückes P, Köppler J, Trappe J, Rothbauer U, Koch P, Laufer SA.. (2015) Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.. J Med Chem, 58 (1): (443-456). [PMID:25475894] [10.1021/jm501557a]
125. Ye Q, Mao W, Zhou Y, Xu L, Li Q, Gao Y, Wang J, Li C, Xu Y, Xu Y, Liao H, Zhang L, Gao J, Li J, Pang T.. (2015) Synthesis and biological evaluation of 3-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-4-(indol-3-yl)-maleimides as potent, selective GSK-3β inhibitors and neuroprotective agents.. Bioorg Med Chem, 23 (5): (1179-1188). [PMID:25662701] [10.1016/j.bmc.2014.12.026]
126. Ai Y, Kang F, Huang Z, Xue X, Lai Y, Peng S, Tian J, Zhang Y.. (2015) Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer.. J Med Chem, 58 (5): (2452-2464). [PMID:25675144] [10.1021/jm5019302]
127. Yan R, Chuang HC, Kapuriya N, Chou CC, Lai PT, Chang HW, Yang CN, Kulp SK, Chen CS.. (2015) Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors.. J Med Chem, 58 (5): (2290-2298). [PMID:25689347] [10.1021/jm501751b]
128. Lawrence HR, Mahajan K, Luo Y, Zhang D, Tindall N, Huseyin M, Gevariya H, Kazi S, Ozcan S, Mahajan NP, Lawrence NJ.. (2015) Development of novel ACK1/TNK2 inhibitors using a fragment-based approach.. J Med Chem, 58 (6): (2746-2763). [PMID:25699576] [10.1021/jm501929n]
129. Zhang CH, Zheng MW, Li YP, Lin XD, Huang M, Zhong L, Li GB, Zhang RJ, Lin WT, Jiao Y, Wu XA, Yang J, Xiang R, Chen LJ, Zhao YL, Cheng W, Wei YQ, Yang SY.. (2015) Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.. J Med Chem, 58 (9): (3957-3974). [PMID:25835317] [10.1021/acs.jmedchem.5b00270]
130. Kommagalla Y, Cornea S, Riehle R, Torchilin V, Degterev A, Ramana CV.. (2014) Optimization of the anti-cancer activity of phosphatidylinositol-3 kinase pathway inhibitor PITENIN-1: switching a thiourea with 1,2,3-triazole.. Medchemcomm, 5 (9): (1359-1363). [PMID:25505943] [10.1039/c4md00109e]
131. Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar A, Bharate SB.. (2015) Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.. Bioorg Med Chem Lett, 25 (15): (2948-2952). [PMID:26048785] [10.1016/j.bmcl.2015.05.034]
132. Boland S, Bourin A, Alen J, Geraets J, Schroeders P, Castermans K, Kindt N, Boumans N, Panitti L, Vanormelingen J, Fransen S, Van de Velde S, Defert O.. (2015) Design, synthesis and biological characterization of selective LIMK inhibitors.. Bioorg Med Chem Lett, 25 (18): (4005-4010). [PMID:26233434] [10.1016/j.bmcl.2015.07.009]
133. Miklossy G, Youn UJ, Yue P, Zhang M, Chen CH, Hilliard TS, Paladino D, Li Y, Choi J, Sarkaria JN, Kawakami JK, Wongwiwatthananukit S, Chen Y, Sun D, Chang LC, Turkson J.. (2015) Hirsutinolide Series Inhibit Stat3 Activity, Alter GCN1, MAP1B, Hsp105, G6PD, Vimentin, TrxR1, and Importin α-2 Expression, and Induce Antitumor Effects against Human Glioma.. J Med Chem, 58 (19): (7734-7748). [PMID:26331426] [10.1021/acs.jmedchem.5b00686]
134. Nakano H, Hasegawa T, Saito N, Furukawa K, Mukaida N, Kojima H, Okabe T, Nagano T.. (2015) Design and synthesis of an in vivo-efficacious PIM3 kinase inhibitor as a candidate anti-pancreatic cancer agent.. Bioorg Med Chem Lett, 25 (24): (5687-5693). [PMID:26547690] [10.1016/j.bmcl.2015.10.098]
135. Simon-Szabó L, Kokas M, Greff Z, Boros S, Bánhegyi P, Zsákai L, Szántai-Kis C, Vantus T, Mandl J, Bánhegyi G, Vályi-Nagy I, Őrfi L, Ullrich A, Csala M, Kéri G.. (2016) Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes.. Bioorg Med Chem Lett, 26 (2): (424-428). [PMID:26704265] [10.1016/j.bmcl.2015.11.099]
136. Aytaç PS, Durmaz I, Houston DR, Çetin-Atalay R, Tozkoparan B.. (2016) Novel triazolothiadiazines act as potent anticancer agents in liver cancer cells through Akt and ASK-1 proteins.. Bioorg Med Chem, 24 (4): (858-872). [PMID:26810835] [10.1016/j.bmc.2016.01.013]
137. Lee NY, Chung KS, Jin JS, Bang KS, Eom YJ, Hong CH, Nugroho A, Park HJ, An HJ.. (2015) Effect of Chicoric Acid on Mast Cell-Mediated Allergic Inflammation in Vitro and in Vivo.. J Nat Prod, 78 (12): (2956-2962). [PMID:26593037] [10.1021/acs.jnatprod.5b00668]
138. Wu F, Zhou C, Yao Y, Wei L, Feng Z, Deng L, Song Y.. (2016) 3-(Piperidin-4-ylmethoxy)pyridine Containing Compounds Are Potent Inhibitors of Lysine Specific Demethylase 1.. J Med Chem, 59 (1): (253-263). [PMID:26652247] [10.1021/acs.jmedchem.5b01361]
139. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J.. (2016) 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.. J Med Chem, 59 (4): (1388-1409). [PMID:26741168] [10.1021/acs.jmedchem.5b01635]
140. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J.. (2016) Identification of quinones as novel PIM1 kinase inhibitors.. Bioorg Med Chem Lett, 26 (13): (3187-3191). [PMID:27173800] [10.1016/j.bmcl.2016.04.079]
141. Gu X, Huang Z, Ren Z, Tang X, Xue R, Luo X, Peng S, Peng H, Lu B, Tian J, Zhang Y.. (2017) Potent Inhibition of Nitric Oxide-Releasing Bifendate Derivatives against Drug-Resistant K562/A02 Cells in Vitro and in Vivo.. J Med Chem, 60 (3): (928-940). [PMID:28068095] [10.1021/acs.jmedchem.6b01075]
142. Juen L, Brachet-Botineau M, Parmenon C, Bourgeais J, Hérault O, Gouilleux F, Viaud-Massuard MC, Prié G.. (2017) New Inhibitor Targeting Signal Transducer and Activator of Transcription 5 (STAT5) Signaling in Myeloid Leukemias.. J Med Chem, 60 (14): (6119-6136). [PMID:28654259] [10.1021/acs.jmedchem.7b00369]
143. Wang S, Xu L, Lu YT, Liu YF, Han B, Liu T, Tang J, Li J, Wu J, Li JY, Yu LF, Yang F.. (2017) Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet β-cells from apoptosis.. Eur J Med Chem, 130 (195-208). [PMID:28249207] [10.1016/j.ejmech.2017.02.048]
144. Wang Y, Sun Y, Cao R, Liu D, Xie Y, Li L, Qi X, Huang N.. (2017) In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery.. J Med Chem, 60 (20): (8552-8564). [PMID:28945083] [10.1021/acs.jmedchem.7b01075]
145. Wagman AS, Boyce RS, Brown SP, Fang E, Goff D, Jansen JM, Le VP, Levine BH, Ng SC, Ni ZJ, Nuss JM, Pfister KB, Ramurthy S, Renhowe PA, Ring DB, Shu W, Subramanian S, Zhou XA, Shafer CM, Harrison SD, Johnson KW, Bussiere DE.. (2017) Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.. J Med Chem, 60 (20): (8482-8514). [PMID:29016121] [10.1021/acs.jmedchem.7b00922]
146. Huang H, Liu T, Guo J, Yu L, Wu X, He Y, Li D, Liu J, Zhang K, Zheng X, Goodin S.. (2017) Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.. Bioorg Med Chem Lett, 27 (11): (2286-2291). [PMID:28462831] [10.1016/j.bmcl.2017.04.047]
147. Shi Y, Challa S, Sang P, She F, Li C, Gray GM, Nimmagadda A, Teng P, Odom T, Wang Y, van der Vaart A, Li Q, Cai J.. (2017) One-Bead-Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2.. J Med Chem, 60 (22): (9290-9298). [PMID:29111705] [10.1021/acs.jmedchem.7b01280]
148. Zhou D, Springer MZ, Xu D, Liu D, Hudmon A, Macleod KF, Meroueh SO.. (2017) Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth.. Bioorg Med Chem, 25 (12): (2995-3005). [PMID:28438385] [10.1016/j.bmc.2017.03.048]
149. Karelia DN, Sk UH, Singh P, Gowda ASP, Pandey MK, Ramisetti SR, Amin S, Sharma AK.. (2017) Design, synthesis, and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual Topoisomerase-IIα and Akt pathway inhibitor, and evaluation of its anti-melanoma activity.. Eur J Med Chem, 135 (282-295). [PMID:28458134] [10.1016/j.ejmech.2017.04.052]
150. Zou Y, Zhao D, Yan C, Ji Y, Liu J, Xu J, Lai Y, Tian J, Zhang Y, Huang Z.. (2018) Novel Ligustrazine-Based Analogs of Piperlongumine Potently Suppress Proliferation and Metastasis of Colorectal Cancer Cells in Vitro and in Vivo.. J Med Chem, 61 (5): (1821-1832). [PMID:29424539] [10.1021/acs.jmedchem.7b01096]
151. Yeon Park J, Young Kim H, Shibamoto T, Su Jang T, Cheon Lee S, Suk Shim J, Hahm DH, Lee HJ, Lee S, Sung Kang K.. (2017) Beneficial effects of a medicinal herb, Cirsium japonicum var. maackii, extract and its major component, cirsimaritin on breast cancer metastasis in MDA-MB-231 breast cancer cells.. Bioorg Med Chem Lett, 27 (17): (3968-3973). [PMID:28784292] [10.1016/j.bmcl.2017.07.070]
152. Sugimoto Y, Sawant DB, Fisk HA, Mao L, Li C, Chettiar S, Li PK, Darby MV, Brueggemeier RW.. (2017) Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.. Bioorg Med Chem, 25 (7): (2156-2166). [PMID:28259529] [10.1016/j.bmc.2017.02.030]
153. Chen J, Wang T, Xu S, Zhang P, Lin A, Wu L, Yao H, Xie W, Zhu Z, Xu J.. (2017) Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.. Eur J Med Chem, 135 (414-423). [PMID:28463784] [10.1016/j.ejmech.2017.04.045]
154. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031]
155. Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T.. (2018) Identification and biological evaluation of thiazole-based inverse agonists of RORγt.. Bioorg Med Chem Lett, 28 (9): (1446-1455). [PMID:29631962] [10.1016/j.bmcl.2018.03.093]
156. Wang J, Long L, Chen Y, Xu Y, Zhang L.. (2018) Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.. Bioorg Med Chem Lett, 28 (10): (1817-1824). [PMID:29678463] [10.1016/j.bmcl.2018.04.019]
157. Wang T, Jiang H, Cao S, Chen Q, Cui M, Wang Z, Li D, Zhou J, Wang T, Qiu F, Kang N.. (2017) Baicalin and its metabolites suppresses gluconeogenesis through activation of AMPK or AKT in insulin resistant HepG-2 cells.. Eur J Med Chem, 141 (92-100). [PMID:29028535] [10.1016/j.ejmech.2017.09.049]
158. Solomon VR, Pundir S, Le HT, Lee H.. (2018) Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.. Eur J Med Chem, 143 (1028-1038). [PMID:29232580] [10.1016/j.ejmech.2017.11.097]
159. Altıntop MD, Sever B, Akalın Çiftçi G, Turan-Zitouni G, Kaplancıklı ZA, Özdemir A.. (2018) Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.. Eur J Med Chem, 155 (905-924). [PMID:29966916] [10.1016/j.ejmech.2018.06.049]
160. Thakkar M, Bhuniya D, Kaduskar R, Mengawade T, Naik K, Salunkhe V, Bhalerao A, Kurhade S, Mavinahalli J, Jain V, Petla R, Avaragolla S, Ray S, Rouduri S, Dhanave A, De S, Pathade V, Tambe A, Raje AA, Madgula V, Joshi S, Nadeem A, Bala M, Umrani D, Hariharan N, Kulkarni B, Mookhtiar KA.. (2017) Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 27 (8): (1867-1873). [PMID:28279528] [10.1016/j.bmcl.2017.02.026]
161. Kim SM, Park YJ, Shin MS, Kim HR, Kim MJ, Lee SH, Yun SP, Kwon SH.. (2017) Acacetin inhibits neuronal cell death induced by 6-hydroxydopamine in cellular Parkinson's disease model.. Bioorg Med Chem Lett, 27 (23): (5207-5212). [PMID:29089232] [10.1016/j.bmcl.2017.10.048]
162. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V.. (2017) Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.. Bioorg Med Chem, 25 (24): (6523-6535). [PMID:29089259] [10.1016/j.bmc.2017.10.032]
163. Lim WC, Kim H, Kim YJ, Park SH, Song JH, Lee KH, Lee IH, Lee YK, So KA, Choi KC, Ko H.. (2017) Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer cells.. Bioorg Med Chem Lett, 27 (23): (5337-5343). [PMID:29122484] [10.1016/j.bmcl.2017.09.024]
164. Hu X, He Y, Wu L, Hao Y, Wang Z, Zheng W.. (2017) Novel all-hydrocarbon stapled p110α[E545K] peptides as blockers of the oncogenic p110α[E545K]-IRS1 interaction.. Bioorg Med Chem Lett, 27 (24): (5446-5449). [PMID:29138025] [10.1016/j.bmcl.2017.10.076]
165. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W.. (2018) Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.. Bioorg Med Chem, 26 (3): (590-602). [PMID:29289448] [10.1016/j.bmc.2017.12.020]
166. Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A.. (2018) Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.. J Med Chem, 61 (5): (2104-2110). [PMID:29466002] [10.1021/acs.jmedchem.7b01605]
167. Liu Y, Yin Y, Zhang Z, Li CJ, Zhang H, Zhang D, Jiang C, Nomie K, Zhang L, Wang ML, Zhao G.. (2017) Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity.. Eur J Med Chem, 138 (543-551). [PMID:28704757] [10.1016/j.ejmech.2017.06.067]
168. Sun S, Phrutivorapongkul A, Dibwe DF, Balachandran C, Awale S.. (2018) Chemical Constituents of Thai Citrus hystrix and Their Antiausterity Activity against the PANC-1 Human Pancreatic Cancer Cell Line.. J Nat Prod, 81 (8): (1877-1883). [PMID:30070833] [10.1021/acs.jnatprod.8b00405]
169. Rai R, Dutta RK, Singh S, Yadav DK, Kumari S, Singh H, Gupta RD, Pratap R.. (2018) Synthesis, biological evaluation and molecular docking study of 1-amino-2-aroylnaphthalenes against prostate cancer.. Bioorg Med Chem Lett, 28 (9): (1574-1580). [PMID:29606573] [10.1016/j.bmcl.2018.03.057]
170. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L.. (2018) Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.. Eur J Med Chem, 150 (491-505). [PMID:29549836] [10.1016/j.ejmech.2018.02.080]
171. Lovering F, Morgan P, Allais C, Aulabaugh A, Brodfuehrer J, Chang J, Coe J, Ding W, Dowty H, Fleming M, Frisbie R, Guzova J, Hepworth D, Jasti J, Kortum S, Kurumbail R, Mohan S, Papaioannou N, Strohbach JW, Vincent F, Lee K, Zapf CW.. (2018) Rational approach to highly potent and selective apoptosis signal-regulating kinase 1 (ASK1) inhibitors.. Eur J Med Chem, 145 (606-621). [PMID:29348070] [10.1016/j.ejmech.2017.12.041]
172. Gao JB, Yang SJ, Yan ZR, Zhang XJ, Pu DB, Wang LX, Li XL, Zhang RH, Xiao WL.. (2018) Isolation, Characterization, and Structure-Activity Relationship Analysis of Abietane Diterpenoids from Callicarpa bodinieri as Spleen Tyrosine Kinase Inhibitors.. J Nat Prod, 81 (4): (998-1006). [PMID:29578342] [10.1021/acs.jnatprod.7b01082]
173. Fearon D, Westwood IM, van Montfort RLM, Bayliss R, Jones K, Bavetsias V.. (2018) Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.. Bioorg Med Chem, 26 (11): (3021-3029). [PMID:29764757] [10.1016/j.bmc.2018.04.033]
174. Zhang D, Tong D, Yang D, Sun J, Zhang F, Zhao G.. (2018) Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant.. Medchemcomm, 9 (8): (1340-1350). [PMID:30151089] [10.1039/C8MD00197A]
175. Kumar C, Rasool RU, Iqra Z, Nalli Y, Dutt P, Satti NK, Sharma N, Gandhi SG, Goswami A, Ali A.. (2017) Alkyne-azide cycloaddition analogues of dehydrozingerone as potential anti-prostate cancer inhibitors via the PI3K/Akt/NF-kB pathway.. Medchemcomm, 8 (11): (2115-2124). [PMID:30108729] [10.1039/C7MD00267J]
176. Uko NE, Güner OF, Barnett LMA, Matesic DF, Bowen JP.. (2018) Discovery and biological activity of computer-assisted drug designed Akt pathway inhibitors.. Bioorg Med Chem Lett, 28 (19): (3247-3250). [PMID:30143420] [10.1016/j.bmcl.2018.08.006]
177. Park JY, Park DH, Jeon Y, Kim YJ, Lee J, Shin MS, Kang KS, Hwang GS, Kim HY, Yamabe N.. (2018) Eupatilin inhibits angiogenesis-mediated human hepatocellular metastasis by reducing MMP-2 and VEGF signaling.. Bioorg Med Chem Lett, 28 (19): (3150-3154). [PMID:30177376] [10.1016/j.bmcl.2018.08.034]
178. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (1300-1325). [PMID:30195240] [10.1016/j.ejmech.2018.08.031]
179. Djehal A, Krayem M, Najem A, Hammoud H, Cresteil T, Nebigil CG, Wang D, Yu P, Bentouhami E, Ghanem GE, Désaubry L.. (2018) Targeting prohibitin with small molecules to promote melanogenesis and apoptosis in melanoma cells.. Eur J Med Chem, 155 (880-888). [PMID:29960207] [10.1016/j.ejmech.2018.06.052]
180. Zhan W, Che J, Xu L, Wu Y, Hu X, Zhou Y, Cheng G, Hu Y, Dong X, Li J.. (2019) Discovery of pyrazole-thiophene derivatives as highly Potent, orally active Akt inhibitors.. Eur J Med Chem, 180 (72-85). [PMID:31301565] [10.1016/j.ejmech.2019.07.017]
181. Güzelcan EA, Baxendale IR, Cetin-Atalay R, Baumann M.. (2019) Synthesis of new derivatives of boehmeriasin A and their biological evaluation in liver cancer.. Eur J Med Chem, 166 (243-255). [PMID:30716712] [10.1016/j.ejmech.2019.01.056]
182. Osborne J, Birchall K, Tsagris DJ, Lewis SJ, Smiljanic-Hurley E, Taylor DL, Levy A, Alessi DR, McIver EG.. (2019) Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1.. Bioorg Med Chem Lett, 29 (4): (668-673). [PMID:30554956] [10.1016/j.bmcl.2018.11.058]
183. Ecoy GAU, Chamni S, Suwanborirux K, Chanvorachote P, Chanvorachote P, Chaotham C.. (2019) Jorunnamycin A from Xestospongia sp. Suppresses Epithelial to Mesenchymal Transition and Sensitizes Anoikis in Human Lung Cancer Cells.. J Nat Prod, 82 (7): (1861-1873). [PMID:31260310] [10.1021/acs.jnatprod.9b00102]
184. Li W, Chu J, Fan T, Zhang W, Yao M, Ning Z, Wang M, Sun J, Zhao X, Wen A.. (2019) Design and synthesis of novel 1-phenyl-3-(5-(pyrimidin-4-ylthio)-1,3,4-thiadiazol- 2-yl)urea derivatives with potent anti-CML activity throughout PI3K/AKT signaling pathway.. Bioorg Med Chem Lett, 29 (14): (1831-1835). [PMID:31097376] [10.1016/j.bmcl.2019.05.005]
185. Tang G, Liu L, Wang X, Pan Z.. (2019) Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).. Eur J Med Chem, 173 (167-183). [PMID:30999237] [10.1016/j.ejmech.2019.03.055]
186. Abdelaziz AM, Basnet SKC, Islam S, Li M, Tadesse S, Albrecht H, Gerber C, Yu M, Wang S.. (2019) Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.. Bioorg Med Chem Lett, 29 (18): (2650-2654). [PMID:31362920] [10.1016/j.bmcl.2019.07.043]
187. Heng H, Wang Z, Li H, Huang Y, Lan Q, Guo X, Zhang L, Zhi Y, Cai J, Qin T, Xiang L, Wang S, Chen Y, Lu T, Lu S.. (2019) Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model.. Eur J Med Chem, 176 (248-267). [PMID:31103903] [10.1016/j.ejmech.2019.05.021]
188. Yuan T, Qi B, Jiang Z, Dong W, Zhong L, Bai L, Tong R, Yu J, Shi J.. (2019) Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.. Eur J Med Chem, 178 (468-483). [PMID:31207462] [10.1016/j.ejmech.2019.06.002]
189. Gu C, Stashko MA, Puhl-Rubio AC, Chakraborty M, Chakraborty A, Frye SV, Pearce KH, Wang X, Shears SB, Wang H.. (2019) Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis.. J Med Chem, 62 (3): (1443-1454). [PMID:30624931] [10.1021/acs.jmedchem.8b01593]
190. Zha GF, Rakesh KP, Manukumar HM, Shantharam CS, Long S.. (2019) Pharmaceutical significance of azepane based motifs for drug discovery: A critical review.. Eur J Med Chem, 162 (465-494). [PMID:30469042] [10.1016/j.ejmech.2018.11.031]
191. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P.. (2019) Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.. Eur J Med Chem, 175 (309-329). [PMID:31096153] [10.1016/j.ejmech.2019.04.035]
192. Recagni M, Greco ML, Milelli A, Minarini A, Zaffaroni N, Folini M, Sissi C.. (2019) Distinct biological responses of metastatic castration resistant prostate cancer cells upon exposure to G-quadruplex interacting naphthalenediimide derivatives.. Eur J Med Chem, 177 (401-413). [PMID:31158753] [10.1016/j.ejmech.2019.05.066]
193. Andrews LD, Kane TR, Dozzo P, Haglund CM, Hilderbrandt DJ, Linsell MS, Machajewski T, McEnroe G, Serio AW, Wlasichuk KB, Neau DB, Pakhomova S, Waldrop GL, Sharp M, Pogliano J, Cirz RT, Cohen F.. (2019) Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase.. J Med Chem, 62 (16): (7489-7505). [PMID:31306011] [10.1021/acs.jmedchem.9b00625]
194. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H.. (2019) Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.. Bioorg Med Chem Lett, 29 (7): (873-877). [PMID:30755337] [10.1016/j.bmcl.2019.02.006]
195. Ai Y, Zhu B, Ren C, Kang F, Li J, Huang Z, Lai Y, Peng S, Ding K, Tian J, Zhang Y.. (2016) Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer.. J Med Chem, 59 (5): (1747-1760). [PMID:26891099] [10.1021/acs.jmedchem.5b01203]
196. Mandalapu D, Saini KS, Gupta S, Sharma V, Yaseen Malik M, Chaturvedi S, Bala V, Hamidullah, Thakur S, Maikhuri JP, Wahajuddin M, Konwar R, Gupta G, Sharma VL.. (2016) Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines.. Bioorg Med Chem Lett, 26 (17): (4223-4232). [PMID:27496212] [10.1016/j.bmcl.2016.07.053]
197. Chen Y, Cui Y, Sun X, Wu H, Ou M, Tang Y, Ni S, Li X, Zhu J, Mao F, Wang Y, Li J.. (2020) Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer.. Bioorg Med Chem Lett, 30 (14): (127239-127239). [PMID:32527541] [10.1016/j.bmcl.2020.127239]
198. Kaur S, Bansal Y, Kumar R, Bansal G.. (2020) A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.. Bioorg Med Chem, 28 (5): (115327-115327). [PMID:31992476] [10.1016/j.bmc.2020.115327]
199. Lategahn J,Hardick J,Grabe T,Niggenaber J,Jeyakumar K,Keul M,Tumbrink HL,Becker C,Hodson L,Kirschner T,Klövekorn P,Ketzer J,Baumann M,Terheyden S,Unger A,Weisner J,Müller MP,van Otterlo WAL,Bauer S,Rauh D. (2020) Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach.. J Med Chem, 63 (20.0): (11725-11755). [PMID:32931277] [10.1021/acs.jmedchem.0c00870]
200. Grant CV,Cai S,Risinger AL,Liang H,O'Keefe BR,Doench JG,Cichewicz RH,Mooberry SL. (2020) CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells.. J Nat Prod, 83 (10.0): (3080-3092). [PMID:33021790] [10.1021/acs.jnatprod.0c00642]
201. Zhu P,Qian J,Xu Z,Meng C,Liu J,Shan W,Zhu W,Wang Y,Yang Y,Zhang W,Zhang Y,Ling Y. (2020) Piperlonguminine and Piperine Analogues as TrxR Inhibitors that Promote ROS and Autophagy and Regulate p38 and Akt/mTOR Signaling.. J Nat Prod, 83 (10.0): (3041-3049). [PMID:33026807] [10.1021/acs.jnatprod.0c00599]
202. Yu M,Zeng M,Pan Z,Wu F,Guo L,He G. (2020) Discovery of novel akt1 inhibitor induces autophagy associated death in hepatocellular carcinoma cells.. Eur J Med Chem, 189 (112076-112076). [PMID:32007668] [10.1016/j.ejmech.2020.112076]
203. Matheson, Christopher J., Coxon, Christopher R., Bayliss, Richard, Boxall, Kathy, Carbain, Benoit, Fry, Andrew M., Hardcastle, Ian R., Harnor, Suzannah J., Mas-Droux, Corine, Newell, David R., Richards, Mark W., Sivaprakasam, Mangaleswaran, Turner, David, Griffin, Roger J., Golding, Bernard T., Cano, Celine. (2020) 2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase. RSC Med Chem, 11 (6): (707-731). [PMID:33479670] [10.1039/d0md00074d]
204. Kumar JS,Thirupataiah B,Medishetti R,Ray A,Bele SD,Hossain KA,Reddy GS,Edwin RK,Joseph A,Kumar N,Shenoy GG,Rao CM,Pal M. (2020) Rosuvastatin based novel 3-substituted isocoumarins / 3-alkylidenephthalides: Ultrasound assisted synthesis and identification of new anticancer agents.. Eur J Med Chem, 201 (112335-112335). [PMID:32599323] [10.1016/j.ejmech.2020.112335]
205. Coffer, P J PJ and Woodgett, J R JR.. (1992) Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families.. European journal of biochemistry, (1): [PMID:1533586]
206. Coffer, P J PJ and Woodgett, J R JR.. (1991) Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families.. European journal of biochemistry, (15): [PMID:1718748]
207. Jones, P F PF, Jakubowicz, T T, Pitossi, F J FJ, Maurer, F F and Hemmings, B A BA.. (1991) Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily.. Proceedings of the National Academy of Sciences of the United States of America, (15): [PMID:1851997]
208. Alessi, D R DR and 6 more authors.. (1996) Mechanism of activation of protein kinase B by insulin and IGF-1.. The EMBO journal, (2): [PMID:8978681]
209. Walker, K S KS and 5 more authors.. (1998) Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha.. The Biochemical journal, (1): [PMID:9512493]
210. Du, K K and Montminy, M M.. (1998) CREB is a regulatory target for the protein kinase Akt/PKB.. The Journal of biological chemistry, (4): [PMID:9829964]
211. Rena, G G, Guo, S S, Cichy, S C SC, Unterman, T G TG and Cohen, P P.. (1999) Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B.. The Journal of biological chemistry, (11): [PMID:10358075]
212. Zimmermann, S S and Moelling, K K.. (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B).. Science (New York, N.Y.), (26): [PMID:10576742]
213. Pekarsky, Y Y and 8 more authors.. (2000) Tcl1 enhances Akt kinase activity and mediates its nuclear translocation.. Proceedings of the National Academy of Sciences of the United States of America, (28): [PMID:10716693]
214. Koh, H H and 5 more authors.. (2000) Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced protein kinase C-related kinase 2 (PRK2) cleavage.. The Journal of biological chemistry, (3): [PMID:10926925]
215. Laine, J J, Künstle, G G, Obata, T T, Sha, M M and Noguchi, M M.. (2000) The protooncogene TCL1 is an Akt kinase coactivator.. Molecular cell, [PMID:10983986]
216. Kim, A H AH, Khursigara, G G, Sun, X X, Franke, T F TF and Chao, M V MV.. (2001) Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1.. Molecular and cellular biology, [PMID:11154276]
217. Matsubara, A A and 5 more authors.. (2001) Isolation and characterization of the human AKT1 gene, identification of 13 single nucleotide polymorphisms (SNPs), and their lack of association with Type II diabetes.. Diabetologia, [PMID:11508278]
218. Maira, S M SM and 6 more authors.. (2001) Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane.. Science (New York, N.Y.), (12): [PMID:11598301]
219. Künstle, Gerald G and 8 more authors.. (2002) Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1.. Molecular and cellular biology, [PMID:11839817]
220. Kane, Susan S and 6 more authors.. (2002) A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain.. The Journal of biological chemistry, (21): [PMID:11994271]
221. Fujita, Naoya N, Sato, Saori S, Katayama, Kazuhiro K and Tsuruo, Takashi T.. (2002) Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization.. The Journal of biological chemistry, (9): [PMID:12042314]
222. Conus, Nelly Marmy NM, Hannan, Katherine M KM, Cristiano, Briony E BE, Hemmings, Brian A BA and Pearson, Richard B RB.. (2002) Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase.. The Journal of biological chemistry, (11): [PMID:12149249]
223. Manning, Brendan D BD, Tee, Andrew R AR, Logsdon, M Nicole MN, Blenis, John J and Cantley, Lewis C LC.. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway.. Molecular cell, [PMID:12150915]
224. Thomas, Christine C CC, Deak, Maria M, Alessi, Dario R DR and van Aalten, Daan M F DM.. (2002) High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate.. Current biology : CB, (23): [PMID:12176338]
225. Shin, Incheol I and 6 more authors.. (2002) PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.. Nature medicine, [PMID:12244301]
226. Heilig, Roland R and 98 more authors.. (2003) The DNA sequence and analysis of human chromosome 14.. Nature, (6): [PMID:12508121]
227. He, Zhiwei Z and 5 more authors.. (2003) Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1.. The Journal of biological chemistry, (21): [PMID:12529330]
228. Lennartsson, Johan J, Wernstedt, Christer C, Engström, Ulla U, Hellman, Ulf U and Rönnstrand, Lars L.. (2003) Identification of Tyr900 in the kinase domain of c-Kit as a Src-dependent phosphorylation site mediating interaction with c-Crk.. Experimental cell research, (1): [PMID:12878163]
229. Remy, Ingrid I and Michnick, Stephen W SW.. (2004) Regulation of apoptosis by the Ft1 protein, a new modulator of protein kinase B/Akt.. Molecular and cellular biology, [PMID:14749367]
230. Ahn, Jee-Yin JY and 5 more authors.. (2004) PIKE (phosphatidylinositol 3-kinase enhancer)-A GTPase stimulates Akt activity and mediates cellular invasion.. The Journal of biological chemistry, (16): [PMID:14761976]
231. Kunapuli, Padmaja P, Kasyapa, Chitta S CS, Hawthorn, Lesleyann L and Cowell, John K JK.. (2004) LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway.. The Journal of biological chemistry, (28): [PMID:15047712]
232. Ahn, Jee-Yin JY, Hu, Yuanxin Y, Kroll, Todd G TG, Allard, Paulette P and Ye, Keqiang K.. (2004) PIKE-A is amplified in human cancers and prevents apoptosis by up-regulating Akt.. Proceedings of the National Academy of Sciences of the United States of America, (4): [PMID:15118108]
233. Rönnstrand, L L.. (2004) Signal transduction via the stem cell factor receptor/c-Kit.. Cellular and molecular life sciences : CMLS, [PMID:15526160]
234. Ivanov, Vladimir N VN and Hei, Tom K TK.. (2005) Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway.. Oncogene, (20): [PMID:15580309]
235. Cartlidge, Robert A RA and 5 more authors.. (2005) The tRNA methylase METTL1 is phosphorylated and inactivated by PKB and RSK in vitro and in cells.. The EMBO journal, (4): [PMID:15861136]
236. Enomoto, Atsushi A and 9 more authors.. (2005) Akt/PKB regulates actin organization and cell motility via Girdin/APE.. Developmental cell, [PMID:16139227]
237. Tsou, Tsui-Chun TC and 5 more authors.. (2005) Arsenite induces endothelial cytotoxicity by down-regulation of vascular endothelial nitric oxide synthase.. Toxicology and applied pharmacology, (1): [PMID:16239170]
238. Brandts, Christian H CH and 11 more authors.. (2005) Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.. Cancer research, (1): [PMID:16266983]
239. Srinivas, Harish H and 8 more authors.. (2006) Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha.. The Biochemical journal, (1): [PMID:16417524]
240. Zhang, Xiaoling X and 6 more authors.. (2006) Kinetic mechanism of AKT/PKB enzyme family.. The Journal of biological chemistry, (19): [PMID:16540465]
241. Fritzius, Thorsten T and 10 more authors.. (2006) A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.. The Biochemical journal, (1): [PMID:16792529]
242. Héron-Milhavet, Lisa L and 7 more authors.. (2006) Only Akt1 is required for proliferation, while Akt2 promotes cell cycle exit through p21 binding.. Molecular and cellular biology, [PMID:16982699]
243. Schick, Volker V and 9 more authors.. (2006) Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias.. Acta neuropathologica, [PMID:17013611]
244. Van Meter, Timothy E TE, Broaddus, William C WC, Cash, Dana D and Fillmore, Helen H.. (2006) Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.. Cancer, (15): [PMID:17041888]
245. Carpten, John D JD and 23 more authors.. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.. Nature, (26): [PMID:17611497]
246. Jang, Sung-Wuk SW, Yang, Seung-Ju SJ, Srinivasan, Shanthi S and Ye, Keqiang K.. (2007) Akt phosphorylates MstI and prevents its proteolytic activation, blocking FOXO3 phosphorylation and nuclear translocation.. The Journal of biological chemistry, (19): [PMID:17726016]
247. Cinar, Bekir B and 8 more authors.. (2007) The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1.. The EMBO journal, (31): [PMID:17932490]
248. Shome, Debraj D and 7 more authors.. (2008) Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.. Ophthalmology, [PMID:18201764]
249. Han, Edward Kyu-Ho EK, Mcgonigal, Thomas T, Butler, Chris C, Giranda, Vincent L VL and Luo, Yan Y.. () Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is an Akt substrate both in vitro and in cells.. Anticancer research, [PMID:18507042]
250. Sharlow, Elizabeth R ER and 9 more authors.. (2008) Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.. The Journal of biological chemistry, (28): [PMID:18829454]
251. Landgraf, Kyle E KE, Pilling, Carissa C and Falke, Joseph J JJ.. (2008) Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain.. Biochemistry, (25): [PMID:18954143]
252. Jang, Sung-Wuk SW and 6 more authors.. (2009) Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons.. The Journal of biological chemistry, (4): [PMID:19592491]
253. Yang, Wei-Lei WL and 10 more authors.. (2009) The E3 ligase TRAF6 regulates Akt ubiquitination and activation.. Science (New York, N.Y.), (28): [PMID:19713527]
254. Bristow, Jeanne M JM and 5 more authors.. (2009) The Rho-family GEF Asef2 activates Rac to modulate adhesion and actin dynamics and thereby regulate cell migration.. Journal of cell science, (15): [PMID:19934221]
255. Suizu, Futoshi F and 13 more authors.. (2009) The E3 ligase TTC3 facilitates ubiquitination and degradation of phosphorylated Akt.. Developmental cell, [PMID:20059950]
256. Romano, David D and 5 more authors.. (2010) Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt.. Cancer research, (1): [PMID:20086174]
257. Kim, Donghwa D and 5 more authors.. (2010) Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway.. PloS one, (9): [PMID:20231902]
258. Mahajan, Kiran K and 15 more authors.. (2010) Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation.. PloS one, (19): [PMID:20333297]
259. Bobkova, Ekaterina V EV and 9 more authors.. (2010) Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.. The Journal of biological chemistry, (11): [PMID:20385558]
260. Chin, Y Rebecca YR and Toker, Alex A.. (2010) The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.. Molecular cell, (14): [PMID:20471940]
261. Nam, Seon Young SY and 8 more authors.. (2010) Phosphorylation of CLK2 at serine 34 and threonine 127 by AKT controls cell survival after ionizing radiation.. The Journal of biological chemistry, (8): [PMID:20682768]
262. Wu, Wen-I WI and 5 more authors.. (2010) Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition.. PloS one, (23): [PMID:20886116]
263. Kunoh, Tatsuki T and 13 more authors.. (2010) A novel human dynactin-associated protein, dynAP, promotes activation of Akt, and ergosterol-related compounds induce dynAP-dependent apoptosis of human cancer cells.. Molecular cancer therapeutics, [PMID:20978158]
264. Rodgers, Joseph T; Vogel, Rutger O and Puigserver, Pere.. (2011) Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt.. Molecular cell, (18): [PMID:21329884]
265. Joo, Hae Mi HM and 10 more authors.. (2011) Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2.. European journal of cell biology, [PMID:21333377]
266. Heron-Milhavet, Lisa L, Khouya, Nabil N, Fernandez, Anne A and Lamb, Ned J NJ.. (2011) Akt1 and Akt2: differentiating the aktion.. Histology and histopathology, [PMID:21432781]
267. Xie, Xiaoduo X and 7 more authors.. (2011) IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation.. Proceedings of the National Academy of Sciences of the United States of America, (19): [PMID:21464307]
268. Hers, Ingeborg I, Vincent, Emma E EE and Tavaré, Jeremy M JM.. (2011) Akt signalling in health and disease.. Cellular signalling, [PMID:21620960]
269. Sundaresan, Nagalingam R NR and 9 more authors.. (2011) The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy.. Science signaling, (19): [PMID:21775285]
270. Lindhurst, Marjorie J MJ and 39 more authors.. (2011) A mosaic activating mutation in AKT1 associated with the Proteus syndrome.. The New England journal of medicine, (18): [PMID:21793738]
271. Bae, Seunghee S and 16 more authors.. (2012) Akt is negatively regulated by the MULAN E3 ligase.. Cell research, [PMID:22410793]
272. Wang, Shuai and 13 more authors.. (2012) Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling.. PloS one, [PMID:22629392]
273. Sen, Tanusree T and 7 more authors.. (2012) OGDHL is a modifier of AKT-dependent signaling and NF-κB function.. PloS one, [PMID:23152800]
274. Orloff, Mohammed S MS and 6 more authors.. (2013) Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.. American journal of human genetics, (10): [PMID:23246288]
275. Peng, Bo B, Gu, Yixue Y, Xiong, Yan Y, Zheng, Guopei G and He, Zhimin Z.. (2012) Microarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma.. PloS one, [PMID:23251525]
276. Yao, Yixin Y and 13 more authors.. (2013) BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.. Science signaling, (8): [PMID:23300339]
277. Rokudai, Susumu S and 5 more authors.. (2013) MOZ increases p53 acetylation and premature senescence through its complex formation with PML.. Proceedings of the National Academy of Sciences of the United States of America, (5): [PMID:23431171]
278. Cipriano, Rocky R and 5 more authors.. (2013) FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.. Oncotarget, [PMID:23676467]
279. Zhuo, De-Xiang DX and 7 more authors.. (2013) CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.. PloS one, [PMID:23799035]
280. Singel, Stina M SM and 13 more authors.. (2014) KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.. Neoplasia (New York, N.Y.), [PMID:24784001]
281. Seo, Gil Ju and 9 more authors.. (2015) Akt Kinase-Mediated Checkpoint of cGAS DNA Sensing Pathway.. Cell reports, (13): [PMID:26440888]
282. Yu, Jia J and 9 more authors.. (2017) Regulation of Serine-Threonine Kinase Akt Activation by NAD+-Dependent Deacetylase SIRT7.. Cell reports, (31): [PMID:28147277]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.

SKU	Size	Availability	Price
Ab087937-10μl	10μl	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$66.90
Ab087937-50μl	50μl	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$198.90
Ab087937-100μl	100μl	Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!	$321.90
Ab087937-1ml	1ml	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,937.90

AKT1 Mouse mAb - Primary antibody, for WB,Flow,ELISA,IF,ICC various applications, from Human, generated in Mouse, specific to AKT1, IgG1

Basic Description

Product Properties

Images

Associated Targets(Human)

Mechanisms of Action

Application

Certificates

Certificate of Analysis(COA)

Related Documents

FAQs and Articles

Citations of This Product

References

Solution Calculators

Molarity Calculator

Dilution Calculator

Reconstitution Calculator